Lear Corporation (LEA) will host a conference call at 9:00 AM ET on October 30, 2026, to discuss Q3 26 earnings results.
To access the live webcast, log on to https://ir.lear.com/events-and-presentations
To listen to the call, dial 877-883-0383 or (International) 412-902-6506, Conference code 5619744.
For comments and feedback contact: [email protected]
Business News
October 30, 2026 09:12 ET A key date in rare disease research. BridgeBio Pharma’s BBP-418 is under FDA Priority Review for limb-girdle muscular dystrophy type 2I/R9, a rare genetic disease with no approved treatment. The FDA decision is targeted for November 27. If approved, BBP-418 could become the first approved therapy for any form of limb-girdle muscular dystrophy.